Literature DB >> 35815177

Lidocaine Ineffectiveness Suggests New Psychopharmacology Drug Target.

Mark Mintz1, Victor Badner1, Lynn K Feldman1, Pnina Mintz1, Mana Saraghi1, Jonathan Diaz1, Irina Mezhebovsky1, Irene Axelrod1, Joseph Gleeson1, Chang Liu1, Cathy Smith1, Helen Chow1, David Zurakowski1, Michael M Segal1.   

Abstract

Objectives: The mechanism of many neuropsychiatric disorders remains unknown, but the ineffectiveness of the sodium channel blocker lidocaine has been suggested to be a biomarker for Attention Deficit Hyperactivity Disorder (ADHD) and a severe form of Premenstrual Syndrome (PMS) that is considered psychiatric. We conducted single-arm double-blind clinical trials to test whether lidocaine ineffectiveness can be used as a biomarker to identify people with these conditions and provide a clue as to the molecular mechanism and potential psychopharmacological intervention. Experimental Design: We developed a noninvasive taste test for lidocaine ineffectiveness, validated by comparing lidocaine injections to pain testing in 12 subjects, and assessed it in individuals with ADHD and PMS. Principal Observations: Lidocaine ineffectiveness had a strong association in women with ADHD + PMS in a sample of 53 subjects and controls (p < 0.001). Conclusions: These results suggest the possibility of the biological understanding of the combination of ADHD and PMS that is characteristic of the psychiatric disorder Premenstrual Dysphoric Disorder (PMDD). These results and comparison to family pedigrees of a neuromuscular channelopathy with overlapping symptoms suggest the possibility that the clinical phenotype in PMDD is produced by sensory overstimulation, and amenable to molecular understanding and treatment.
Copyright © 1964–2022 by MedWorks Media Inc, Los Angeles, CA All rights reserved. Printed in the United States.

Entities:  

Keywords:  attention deficit hyperactivity disorder (ADHD); channelopathies; hypokalemic periodic paralysis; lidocaine; premenstrual dysphoric disorder (PMDD)

Mesh:

Substances:

Year:  2022        PMID: 35815177      PMCID: PMC9235314     

Source DB:  PubMed          Journal:  Psychopharmacol Bull        ISSN: 0048-5764


  20 in total

1.  Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine.

Authors:  S H Kennedy; B S Eisfeld; S E Dickens; J R Bacchiochi; R M Bagby
Journal:  J Clin Psychiatry       Date:  2000-04       Impact factor: 4.384

Review 2.  The strange case of Dr. Jekyll and Ms. Hyde: how PMS became a cultural phenomenon and a psychiatric disorder.

Authors:  Joan C Chrisler; Paula Caplan
Journal:  Annu Rev Sex Res       Date:  2002

Review 3.  The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder (PMS/PMDD).

Authors:  Uriel Halbreich; Jeff Borenstein; Terry Pearlstein; Linda S Kahn
Journal:  Psychoneuroendocrinology       Date:  2003-08       Impact factor: 4.905

4.  Daily Record of Severity of Problems (DRSP): reliability and validity.

Authors:  J Endicott; J Nee; W Harrison
Journal:  Arch Womens Ment Health       Date:  2005-09-20       Impact factor: 3.633

5.  Hypokalemic sensory overstimulation.

Authors:  Michael M Segal; Gary F Rogers; Howard L Needleman; Catherine A Chapman
Journal:  J Child Neurol       Date:  2007-12       Impact factor: 1.987

6.  Premenstrual dysphoric disorder: burden of illness and treatment update.

Authors:  Teri Pearlstein; Meir Steiner
Journal:  J Psychiatry Neurosci       Date:  2008-07       Impact factor: 6.186

7.  Longitudinal population-based twin study of retrospectively reported premenstrual symptoms and lifetime major depression.

Authors:  K S Kendler; L M Karkowski; L A Corey; M C Neale
Journal:  Am J Psychiatry       Date:  1998-09       Impact factor: 18.112

Review 8.  Premenstrual Syndrome and Premenstrual Dysphoric Disorder.

Authors:  Sabrina Hofmeister; Seth Bodden
Journal:  Am Fam Physician       Date:  2016-08-01       Impact factor: 3.292

9.  Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome.

Authors:  P J Schmidt; L K Nieman; M A Danaceau; L F Adams; D R Rubinow
Journal:  N Engl J Med       Date:  1998-01-22       Impact factor: 91.245

10.  Premenstrual dysphoric disorder as a correlate of suicidal ideation, plans, and attempts among a nationally representative sample.

Authors:  Corey E Pilver; Daniel J Libby; Rani A Hoff
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2012-07-03       Impact factor: 4.328

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.